Arrowhead Research Release Capital to Invest in Nanotechnology Ventures

Arrowhead Research Corporation, announced today that it has entered into definitive agreements to sell 2,849,446 units consisting of restricted common stock and warrants to purchase restricted common stock to a large institutional money manager, York Capital Management and select accredited investors. Global Crown Capital, LLC acted as the exclusive placement agent for the private placement.

The capital is expected to be used primarily to expand operations at Arrowhead’s majority-owned subsidiary, Unidym, and to make new investments in nanotechnology ventures. Unidym recently merged with Carbon Nanotechnologies, Inc., a world leader in carbon nanotube manufacturing.

“Since our original investment last year, Arrowhead has made demonstrable progress in each of their businesses,” stated Alexander Klabin at York Capital Management. “We are pleased to continue to support their growth by participating in this private offering."

“Global Crown Capital has shown commitment to nurturing companies in the expanding field of nanotechnology and brought an institution of exceptional caliber to this deal," said R. Bruce Stewart, Arrowhead’s chairman. "Arrowhead is well capitalized to continue to implement its current business plan."

Under the terms of the agreements, the investors will purchase 2,849,446 newly-issued shares of restricted common stock at $5.78 per share. Additionally, the investors will receive, in the aggregate, warrants to purchase an additional 712,362 shares of restricted common stock at an exercise price of $7.06 per share. The closing of the private financing is scheduled to occur early next week, resulting in aggregate gross proceeds to Arrowhead of approximately $16.5 million. The Company has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock issued in the private placement and the shares of common stock issued upon exercise of the warrants.

The shares of common stock and warrants offered for sale in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange commission or an applicable exemption from the registration requirements. The shares and warrants were offered and will be sold only to institutional and accredited investors.

This news release is not an offer to sell or the solicitation of an offer to buy the shares of common stock or warrants to purchase shares of common stock or any other securities of the Company.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Arrowhead Pharmaceutical. (2019, March 19). Arrowhead Research Release Capital to Invest in Nanotechnology Ventures. AZoNano. Retrieved on December 04, 2024 from https://www.azonano.com/news.aspx?newsID=4138.

  • MLA

    Arrowhead Pharmaceutical. "Arrowhead Research Release Capital to Invest in Nanotechnology Ventures". AZoNano. 04 December 2024. <https://www.azonano.com/news.aspx?newsID=4138>.

  • Chicago

    Arrowhead Pharmaceutical. "Arrowhead Research Release Capital to Invest in Nanotechnology Ventures". AZoNano. https://www.azonano.com/news.aspx?newsID=4138. (accessed December 04, 2024).

  • Harvard

    Arrowhead Pharmaceutical. 2019. Arrowhead Research Release Capital to Invest in Nanotechnology Ventures. AZoNano, viewed 04 December 2024, https://www.azonano.com/news.aspx?newsID=4138.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.